After a very competitive selection process, hemotune is 1 of 11 European start-ups and 1 of 2 Swiss startups that were selected to receive the highly coveted EIT Health funding. We thank EIT Health for the chance to speed up our development activities in order to bring our live-saving sepsis therapy to the clinics as soon as possible. Since sepsis is also one of the leading causes of death in COVID-19, hemotune will also use the EIT Health funding to adapt hemotune's revolutionary blood purification technology to treat COVID-19 patients.
EIT Health has awarded a total of 5.5 million euros to start-ups in Europe to support with business continuity in response to the disruptions caused by the COVID-19 pandemic. The Start-up Rescue Instrument was initiated by EIT Health in May and called on highly innovative biotech, medtech and digital health start-ups to apply to receive up to €500,000 in co-investment from EIT Health, in return for options.
To find out more about the EIT Health , please visit eithealth.eu.
See also EIT Health press release (09.07.2020).